Hyperparathyroidism and anemia in chronic renal failure. 1982

D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard

The clinical course of an adolescent on chronic hemodialysis with severe hyperparathyroidism, osteodystrophy and profound anemia is described. After 1,25,dihydroxycholecalciferol was instituted for therapy, bone disease improved as evidenced by radiographic findings. Transfusion requirements diminished and bone marrow fibrosis on serial biopsies decreased significantly. These therapeutic results link hyperparathyroidism with the pathogenesis of anemia in chronic renal failure.

UI MeSH Term Description Entries
D006961 Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D012080 Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. Renal Osteodystrophy,Renal Rickets,Rickets, Renal,CKD-MBD,Osteodystrophy, Renal,Chronic Kidney Disease Mineral and Bone Disorder,Osteodystrophies, Renal,Renal Osteodystrophies
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000740 Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN. Anemias
D055728 Primary Myelofibrosis A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone. Agnogenic Myeloid Metaplasia,Bone Marrow Fibrosis,Chronic Idiopathic Myelofibrosis,Fibrosis, Bone Marrow,Idiopathic Myelofibrosis,Myelofibrosis,Myelofibrosis With Myeloid Metaplasia,Myeloid Metaplasia,Myelosclerosis,Myelosis, Nonleukemic,Agnogenic Myeloid Metaplasias,Bone Marrow Fibroses,Fibroses, Bone Marrow,Metaplasia, Agnogenic Myeloid,Metaplasia, Myeloid,Metaplasias, Agnogenic Myeloid,Metaplasias, Myeloid,Myelofibroses,Myelofibroses, Primary,Myelofibrosis, Primary,Myeloid Metaplasia, Agnogenic,Myeloid Metaplasias,Myeloid Metaplasias, Agnogenic,Myeloscleroses,Myeloses, Nonleukemic,Nonleukemic Myeloses,Nonleukemic Myelosis,Primary Myelofibroses

Related Publications

D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
January 2000, American journal of nephrology,
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
March 1981, Archives of internal medicine,
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
December 1977, Clinical endocrinology,
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
September 1970, Lancet (London, England),
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
January 1983, Nephron,
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
January 1996, Nephron,
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
May 1973, Urological research,
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
January 1983, Scandinavian journal of urology and nephrology. Supplementum,
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
January 1981, Annals of clinical and laboratory science,
D F Geary, and R S Fennell, and R C Braylan, and A Iravani, and E H Garin, and G A Richard
January 1972, Acta medica Iugoslavica,
Copied contents to your clipboard!